Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Samsung Enters the Era of “Physical AI” and Robotics; Shares Rise 3% 🤖
Economic calendar: Strong reading from the UK labour market, German ZEW in focus
Is Another DeepSeek Moment Coming? Moonshot AI Increases Pressure on AI Giants
Daily Summary: A sell-off with a spin-off